Abby Hardy, Author at BioTuesdays

Developments

PharmaJet launches Nigerian study of Tropis-administered poliovirus vaccine

PharmaJet launched a study in Nigeria to evaluate the intradermal administration of a fractional inactivated poliovirus vaccine (fIPV) using the company’s Tropis ID Needle-free Injection System. Children at 22 urban and...

October 25, 2023

Executive Moves

SAB Biotherapeutics names Michael G. King Jr. as CFO

SAB Biotherapeutics (NASDAQ:SABS) appointed Michael G. King Jr. as CFO, effective Oct 30. Mr. King replaces Russell Beyer, who is expected to step down on Nov. 15 and remain a senior advisor with the company for the...

October 25, 2023

Markets

Cantor starts Adlai Nortye at OW; PT $30

Cantor Fitzgerald launched coverage of Adlai Nortye (NASDAQ:ANL) with an “overweight” rating and price target of $30. The stock closed at $8.52 on Oct 24. The company is focused on the discovery and development of...

October 25, 2023

Developments

Personalis presents positive NeXT Personal assay data in early-stage lung cancer

Personalis (NASDAQ:PSNL) presented positive data on its NeXT Personal platform’s ability to detect and monitor residual and recurrent disease (MRD) in patients with early-stage lung cancer. NeXT Personal is a whole...

October 23, 2023

Developments

Anixa Biosciences appoints Dr. Mark Goldberg to Cancer Business Advisory Board

Anixa Biosciences (NASDAQ:ANIX) appointed Dr. Mark Goldberg as the ninth independent member of the company’s Cancer Business Advisory Board (CBAB). “Mark brings valuable clinical expertise in oncology, and his extensive...

October 23, 2023

Markets

JMP starts Vigil Neuroscience at MO; PT $23

JMP Securities initiated coverage of Vigil Neuroscience (NASDAQ:VIGL) with a “market outperform” rating and price target of $23. The stock was quoted at $6.50 midday on Oct 18. Vigil is developing novel therapies for...

October 18, 2023

Feature

Jeeva Informatics’ software platform helping to increase clinical trial efficiency, accessibility

Closely-held Jeeva Informatics has developed a centralized electronic clinical platform that aims to help clinical trial sponsors increase the efficiency of their clinical trials, while expanding trial access to...

October 17, 2023

Developments

Profound Medical’s TULSA-PRO prostate cancer treatment featured by AARP as medical breakthrough

Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO technology was featured as a medical breakthrough in an Oct. 13 AARP article. The article introduces 57-year-old Tommy Saul, who was diagnosed with prostate cancer in...

October 13, 2023

Developments

Anixa Biosciences completes first cohort in ovarian cancer CAR-T clinical trial

Anixa Biosciences (NASDAQ:ANIX), in partnership with Moffitt Cancer Center, completed treatment of the first patient cohort in the ongoing clinical trial of Anixa’s novel chimeric antigen receptor T-cell (CAR-T) therapy...

October 13, 2023

Developments

SeaStar Medical’s Selective Cytopheretic Device deemed HDE-approvable by FDA

The FDA deemed SeaStar Medical’s (NASDAQ:ICU) Selective Cytopheretic Device (SCD) Pediatric (SCD-PED) to be approvable under a Humanitarian Device Exemption (HDE). The HDE exemption would apply to children weighing 10...

October 6, 2023

Author - Abby Hardy

PharmaJet launches Nigerian study of Tropis-administered poliovirus vaccine

SAB Biotherapeutics names Michael G. King Jr. as CFO

Cantor starts Adlai Nortye at OW; PT $30

Personalis presents positive NeXT Personal assay data in early-stage lung cancer

Anixa Biosciences appoints Dr. Mark Goldberg to Cancer Business Advisory Board

JMP starts Vigil Neuroscience at MO; PT $23

Jeeva Informatics’ software platform helping to increase clinical trial efficiency, accessibility

Profound Medical’s TULSA-PRO prostate cancer treatment featured by AARP as medical breakthrough

Anixa Biosciences completes first cohort in ovarian cancer CAR-T clinical trial

SeaStar Medical’s Selective Cytopheretic Device deemed HDE-approvable by FDA

General

More